Unlocking the Power of GLP-1 Receptor Agonists and 16 Hour Fasting Benefits
Abstract
Obesity remains a major global health challenge, with glucagon-like peptide-1 receptor agonists (GLP-1RAs) providing substantial yet sensitive benefits in weight reduction, glycemic control, and cardiovascular protection. Despite robust trial data, real-world persistence is limited by cost, tolerability, and hedonic adaptation. Intermittent fasting and time-restricted eating offer exciting potential for individuals seeking sustainable weight loss.Key Takeaways
